[The treatment of bronchopulmonary aspergillosis with allergic manifestations].
The base of current management of bronchopulmonary aspergillosis with allergic manifestations (BPAAM) is glucocorticosteroid treatment. These hormones are introduced in a mean dose 0.5 mg/kg (by prednisolone) to correct bronchial obstruction, reduce eosinophilia and resolve (completely or partially) infiltrates in the lungs. This being achieved, the dose is lowered to warrant maintenance. Minimal doses or discontinuation of glucocorticosteroids may be used in case of adjuvant indomethacin (0.025 three times a day) or plasmapheresis administration. In remission, fungistatic means with glucocorticosteroids or without them (in the absence of bronchial obstruction) are proper. Inhalations in BPAAM are ineffective. Individual schemes of the disease treatment may vary in wide range.
Antonov
V B
VB
Mitrofanov
V S
VS
Sobolev
A V
AV
Iarobkova
N D
ND
D000935:Antifungal Agents / Q000008:administration & dosage; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005100:Expectorants / Q000008:administration & dosage; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage; D008168:Lung / Q000000981:diagnostic imaging; D011239:Prednisolone / Q000008:administration & dosage; D011859:Radiography; D012074:Remission Induction
D000935:Antifungal Agents; D005100:Expectorants; D011239:Prednisolone; D007213:Indomethacin
Lechenie bronkholegochnogo aspergilleza s allergicheskimi proiavleniiami.